Pharmaceutical Executive-01-01-2019

Pharmaceutical Executive

Pharm Exec’s annual look at what lies ahead for the biopharma industry in the coming months examines eight key trends that are seemingly at tipping points in their evolution and poised to shape the life sciences landscape in 2019.

Pharmaceutical Executive

In this Q&A, American-born David Meek, today CEO of Paris-based multinational Ipsen, discusses the drugmaker's bold global expansion and R&D transformation-driven by revamped leadership, a biotech mindset, and promoting external innovation.

Pharmaceutical Executive

CDER priorities for 2019 include opioids, quality, safety, and innovation.

Pharmaceutical Executive

Pharma companies are increasingly expanding their portfolios into digital health solutions. To find the right partners, there are several key considerations that inform their evaluation and selection.

Pharmaceutical Executive

Leaders at Novartis share how the big pharma is laying the foundations for a potential new operating model as a "medicines and data science company."

Pharmaceutical Executive

Being more human in brand engagement doesn’t mean being less transparent

Issue PDF
Pharmaceutical Executive

January 01, 2019

Click the title above to open the Pharmaceutical January 2019 issue in an interactive PDF format.

Special Sponsored Section
Pharmaceutical Executive

January 01, 2019

Despite market access hurdles, Turkey’s pharmaceutical market holds tremendous growth potential-in both value and volume. But will the country be able to take that final step in creating a regulatory and economic environment that is conducive to further upward development?

Pharmaceutical Executive
From the Editor

January 01, 2019

Highlighting a few topics that just missed the cut for our annual Industry Outlook-but are worth keeping a close eye on.